Peramivir

CAT:
804-HY-17015A-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Peramivir - image 1

Peramivir

  • Description:

    Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19[1][2][3].
  • Product Name Alternative:

    RWJ-270201; BCX-1812
  • UNSPSC:

    12352211
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    ERK; IKK; JNK; p38 MAPK; STAT
  • Type:

    Reference compound
  • Related Pathways:

    JAK/STAT Signaling; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Infection; Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/peramivir.html
  • Purity:

    99.94
  • Solubility:

    1 M HCl : 100 mg/mL|DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)
  • Smiles:

    O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O
  • Molecular Formula:

    C15H28N4O4
  • Molecular Weight:

    328.41
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327.|[2]Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7 (1) : 7345.|[3]Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Launched
  • Isoform:

    ERK1; ERK2; IKK-α; STAT3
  • Citation 01:

    Chemosphere. 2017 Feb:169:550-557.|Emerg Microbes Infect. 2025 Dec;14 (1) :2564308.|Int Immunopharmacol. 2023 Feb:115:109706.|Int J Infect Dis. 2024 Jun 27:107134.|Nat Commun. 2013;4:2854.|NPJ Digit Med. 2025 Nov 21, 8 (1) :712.|PLoS One. 2015 Jun 25;10 (6) :e0131412.|PLoS Pathog. 2024 Feb 14;20 (2) :e1011981.|Sci Rep. 2021 Aug 11;11 (1) :16293.|University of Glasgow. School of Cancer Sciences.|Antimicrob Agents Chemother. 2020 Jun 23;64 (7) :e00222-20.|bioRxiv. 2025 Nov 17:2025.11.17.688839.|PLoS One. 2018 Jul 12;13 (7) :e0200761.
  • CAS Number:

    [330600-85-6]